MedikinaBio, a developer of in vitro diagnostic medical devices for liver cancer, enters into an international joint clinical trial agreement with Mongolia’s National Institute of Medical Research

On October 30, 2023, MediKina Bio (CEO Choi Woo-seong) signed a memorandum of understanding for international joint clinical trials with the National Institute of Medical Research in Mongolia (Director L. Tulgaa) at the Gyeonggi Creative Economy Innovation Center Startup Zone for the human application of a new liver cancer in vitro diagnostic medical device where the liver cancer biomarkers are applied.

MediKina Bio utilizes a new liver cancer biomarker-based HDC platform (Hepatocellular Detect & Cure platform, a liver cell carcinoma diagnosis and treatment platform) as a pipeline for liver cancer prognosis prediction, early diagnosis in vitro diagnostic devices, and liver cancer treatment drugs.

Established in 1961, the National Institute of Medical Research in Mongolia serves as a leading medical research institute in Mongolia, undertaking comprehensive research, training, and healthcare services for the advancement of medicine and healthcare. It conducts international collaborative research with institutions such as Stanford University in the United States, Ulm University in Germany, Tokyo University in Japan, the University of Vienna in Austria, and Taipei Medical University in Taiwan, and is currently engaged in a national project for the development of liver cancer in vitro diagnostic devices.

This memorandum of understanding, following discussions with the Mongolian Ministry of Health in June 2023, was signed. With this agreement, MediKina Bio will begin preparations for international joint clinical trials for the liver cancer in vitro diagnostic device being developed. Plans are also underway for various collaborative research utilizing clinical samples of liver cancer patients held by the National Institute of Medical Research in Mongolia.

CEO Choi Woo-seong of MedikinaBio stated, ‘As we are currently preparing for domestic clinical trials, we look forward to cooperation with Mongolia as the first step in international joint clinical trials. We will make efforts for the swift commercialization of the liver cancer in vitro diagnostic device, contributing to the improvement of the survival rate of liver cancer patients and doing our best to activate the global business of our product.

Meanwhile, MediKina Bio focuses on research and development in the research department within the Pangyo Startup Campus operated by the GBSA. It has been selected for the ‘Deep Tech Tips’ project, which is part of the 2023 New Business Outlier Startup 1000+ project supported by the Ministry of SMEs and Startups, providing support for up to 3 years and a maximum of 1.5 billion won for companies with excellent technological capabilities.

For inquiries and connections with Korean tech companies mentioned in this article, contact us at [email protected]. We’re here to facilitate valuable partnerships.

Also Read,

Keep tab on latest news in the Korean startup ecosystem & follow us on LinkedIN, Facebook, and Twitter for more exciting updates and insights.

What’s your thoughts?